Founded in 2015, Pixyl is a French company specializing in medical imaging. The startup announced a €2.2 million fundraising from the investment fund Elaia, with the participation of Bpifrance and Holnest and hopes to accelerate the marketing of its flagship software suite and conquer the market across the Atlantic.

A solution to detect neurological pathologies thanks to artificial intelligence

The start-up Pixyl was founded by a team of researchers from the French National Institute for Research in Computer Science and Control (Inria) and the French National Institute for Health and Medical Research (Inserm). Its three founders, Dr. Senan Doyle, Prof. Florence Forbes and Prof. Michel Dojat, have developed the Pixyl.Neuro software suite capable of detecting common neurological pathologies thanks to artificial intelligence and thus facilitating the work of radiologists.

The tool works on several pathologies: head trauma, neurodegenerative diseases, multiple sclerosis, strokes. Thanks to a machine learning model, Pixyl.Neuro is able to identify “damaged” areas on MRI results. After their detection, the platform provides a detailed report that compiles the biomarkers and can therefore help determine the pathology of the patient.

Fundraising to accelerate commercialization and expand in the US

Radiologists, neurologists and anesthesiologists can use the report to better understand the patient’s case or as part of medical research on one of the neurological pathologies mentioned above. The software can be used in the European Union since it has received the European Conformity Mark (CE).

Thirty-two radiologists and clinicians, as well as Elaia, Bpifrance and Holnest, led a round of financing to provide Pixyl with 2.2 million euros. With this round of financing, this young company based near Grenoble wants to accelerate the marketing of Pixyl.Neuro throughout Europe. In addition, the French start-up aims to conquer the American market with a potential approval from the Federal and Drug Administration (FDA).

Translated from Pixyl lève 2,2 millions d’euros afin de commercialiser sa solution de détection de pathologies neurologiques